| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Warby Parker Inc.$25.87
-3.37 (-11.51%)
Market Cap
2.77 B
EPS
0.01
P/E Ratio
2,331.82 $
Value Trade
52.32 M
SEC Financials
Q1 2026Dilution Risk
Revenue
242.45 M
Operating CF
24.51 M
Total Assets
736.41 M
Total Liabilities
360.60 M
Equity
375.81 M
-1.42 %
Week
-8.52 %
1 Month
-5.7 %
3 Month
7.73 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
288.25 M
Monthly Burn
-
Runway
-
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
2.84 M
52 Week Range
14.96 - 31
% held by Insiders
17.78 %
% held by Institutions
89.62 %
Enterprise Value
2.46 B
Total Shares
107.11 M
Short %
17.67 %
Float Shares
101.11 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in WRBY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
WRBY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-07 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-07 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-07 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-WRBY
Aug 6, 2026▼ -11.5%today
Warby Parker Announces Second Quarter 2026 Results
Warby Parker Inc. reported its financial results for the second quarter of 2026, showcasing a revenue growth of 9.8%. The company also saw a 4.1% increase in active customers, reaching 2.71 million. Additionally, the average revenue per customer rose by 6.6%, contributing to a net income of $4.6 million and an adjusted EBITDA of $32.9 million.
Read more →-WRBY
Jul 16, 2026Warby Parker to Announce Second Quarter 2026 Financial Results on August 6, 2026
Warby Parker Inc. will release its second quarter financial results for 2026 on August 6, 2026. The announcement includes a live conference call at 8:00 a.m. Eastern Time to discuss the results and business outlook. This reflects the company's commitment to transparency and investor engagement.
Read more →-WRBY
May 28, 2026Warby Parker Announces Participation in Upcoming 2026 Baird Global Consumer, Technology & Services Conference
Warby Parker has announced its participation in the upcoming 2026 Baird Global Consumer, Technology & Services Conference. The announcement highlights the company's ongoing engagement with investors and stakeholders in the consumer and technology sectors. Further details about the event and the company's agenda have not been disclosed.
Read more →-WRBY
May 19, 2026▼ -11%on this news
Warby Parker Unveils First Intelligent Eyewear Design
Warby Parker has launched its first intelligent eyewear design, emphasizing privacy protection. This new product aims to integrate technology into everyday eyewear while ensuring user data remains secure. The innovative design is expected to enhance the overall user experience, marking a significant step for the brand in the tech eyewear market.
Read more →-WRBY
May 7, 2026▲ +23.5%on this news· ran to +34% by day 1
Warby Parker Announces First Quarter 2026 Results
Warby Parker Inc. reported strong financial results for Q1 2026, with an 8.3% revenue increase to $242.4 million and a net income of $3.2 million. Active customers grew by 4.8%, reaching 2.69 million, while the company expanded its store count to 337. Despite a decrease in gross margin and a slight dip in net income, the outlook for 2026 remains optimistic with plans for 50 new store openings and the launch of intelligent eyewear.
Read more →-WRBY
Apr 28, 2026Warby Parker Launches Warby Parker Sport, Expanding into the Performance Eyewear Category
Warby Parker has introduced Warby Parker Sport, a new line of performance eyewear designed for both everyday use and active lifestyles. The collection features five frame styles made from lightweight materials and incorporates advanced lens technology for improved vision. The launch reflects the brand's commitment to inclusivity for prescription wearers and its growing presence in sports culture. Warby Parker Sport is available online and in retail locations, with a portion of sales supporting eyewear donations.
Read more →-WRBY
Apr 16, 2026Warby Parker to Announce First Quarter 2026 Financial Results on May 7, 2026
Warby Parker is set to announce its financial results for the first quarter of 2026 on May 7, 2026. This announcement is part of the company's regular financial reporting schedule. Investors and analysts will be keenly awaiting the details of the results to assess the company's performance.
Read more →-WRBY
Feb 9, 2026▼ -5.4%on this news· ran to -16% by day 3
Warby Parker Appoints Adrian Mitchell as Chief Financial Officer
Warby Parker has appointed Adrian Mitchell as the new Chief Financial Officer, effective February 10, 2026. With over 25 years of experience in significant consumer brands, Mitchell aims to enhance the company's growth strategies and leadership. His appointment comes during an ambitious phase for Warby Parker, which includes the launch of AI glasses and a commitment to improving vision accessibility. Mitchell previously led transformative initiatives at Macy's and Crate & Barrel and holds an MBA from Harvard Business School.
Read more →-WRBY
May 20, 2025▲ +15.6%on this news
Warby Parker Partners with Google To Develop Intelligent Eyewear AI-Powered Glasses Will Be Designed for All-Day Wear Announcement Marks First Eyewear Partnership for Android XR Google Commits Up to $150M, Including an E
Warby Parker has announced a partnership with Google to develop AI-powered smart glasses designed for all-day wear. The collaboration, marking Google's first eyewear partnership for Android XR, includes a financial commitment of up to $150 million to support product development. Warby Parker's focus on innovative eyewear design will combine with Google's advanced technology to venture into a new category of connected computing. The first line of intelligent eyewear is slated for launch after 2025, indicating a long-term project ahead.
Read more →-WRBY
Sep 28, 2021Warby Parker Announces Update Regarding Conversion of Shares of Class B Common Stock to Shares of Class A Common Stock
Warby Parker Announces Update Regarding Conversion of Shares of Class B Common Stock to Shares of Class A Common Stock NEW YORK, September 28, 2021. Warby Parker Inc. (the "Company"), a founder-led direct-to-consumer eyewear brand, today announced that, as of September 28, 2021,
Read more →-WRBY
Sep 21, 2021Warby Parker Releases Financial Guidance for the Third Quarter and Fiscal Year 2021 and Fiscal Year 2022
Warby Parker Releases Financial Guidance for the Third Quarter and Fiscal Year 2021 and Fiscal Year 2022 NEW YORK, September 21, 2021. Warby Parker Inc. (the "Company"), a founder-led direct-to-consumer eyewear brand, today issued guidance for the third quarter ending September
Read more →Competitive Position
How WRBY ranks across every disease it competes inCompetitive Position is a premium feature
See how WRBY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial